Introduction
============

Alzheimer's disease (AD) is a neurological disorder caused by the generalized and progressive death of neurons. It is the most widespread neurodegenerative disease of humankind and is accompanied by the accumulation of damaged, misfolded or otherwise abnormal proteins. The main neuromorphological features of AD are amyloid plaques composed largely of the beta-amyloid peptide (Aβ), and neurofibrillary tangles of the microtubule binding protein tau \[[@r1]--[@r3]\]. The accumulation of pathological proteins causing neuronal death is associated with the dysfunction and/or dysregulation of intracellular protein homeostasis systems \[[@r4]--[@r6]\]. The first such system to be impaired is the ubiquitin-proteasome system (UPS). Impairments of the UPS initiate learning and memory deficits in Aβ transgenic animals that is associated with AD development \[[@r4]\]. The UPS marks damaged or misfolded proteins by the covalent attachment of polyubiquitin. Ubiquitylated proteins are then targeted for degradation by the proteasome, a large multiprotein complex possessing both proteasome-associated trypsin- and chymotrypsin-like endoproteolytic activities. Previously, it was shown that the chymotrypsin-like activity of the proteasome was reduced in AD brains \[[@r7],[@r8]\]. Impairment of proteasomal activity in AD is linked to Aβ, a highly amyloidogenic, 39-43 amino acid polypeptide that has been shown to induce apoptosis leading to neuronal cell death \[[@r9],[@r10]\]. Although it is unclear exactly how Aβ leads to apoptosis, Aβ~42~ was shown to directly decrease chymotrypsin-like activity of proteasome \[[@r11],[@r12]\]. However, additional studies in both animal and cellular models of AD, as well as *in vitro,* reported a variety of Aβ effects on the proteasome ranging from decreased to increased and even unchanged activity \[[@r13]--[@r15]\]. Therefore, a greater understanding of the relationship between Aβ and the UPS is needed in order to appreciate how Aβ is toxic to cells and how it induces apoptosis in neurons.

The N-end rule pathway is a part of the UPS and plays critical role in proteolytic signaling and protein-quality control. This pathway recognizes proteins and polypeptides containing N-terminal degradation signals (termed N-degrons) and facilitates their polyubiquitylation thereby facilitating their degradation by the proteasome \[[@r16]--[@r18]\]. The main determinant of an N-degron is a destabilizing N-terminal residue. N-degrons are recognized by specific E3 ubiquitin ligases of the N-end rule pathway. In mammals this pathway consists of the two branches, the Ac/N-end rule pathway, which degrades proteins bearing acetylated N-terminal amino acids \[[@r19]--[@r21]\], and the Arg/N-end rule pathway, which degrades proteins bearing non-acetylated N-terminal arginine, lysine, histidine, leucine, phenylalanine, tryptophan, tyrosine, isoleucine or methionine (if followed by a hydrophobic amino acid) \[[@r17],[@r22]--[@r24]\]. A number of additional N-terminal amino acids are destabilizing as well but require their prior modifications before recognition by N-end rule E3 ligases. N-terminal amidohydrolases catalyze the conversion of asparagine and glutamine into aspartate and glutamate, respectively \[[@r25]--[@r27]\]. Proteins bearing N-terminal aspartate, glutamate and oxidized cysteine are N-terminally arginylated by the arginyl-tRNA-protein transferase (Ate1) \[[@r28]--[@r30]\]. Protein arginylation is a two-step reaction. Initially, tRNA is charged with arginine by aminoacyl-tRNA synthetase (RS) in a manner that requires ATP. Arginine is then transferred from tRNA^Arg^ to the substrate by R-transferase Ate1 \[[@r31],[@r32]\]. Previously, Brower, *et al.* found that Ate1 was capable of arginylating Aβ peptides and that arginylated Aβ~42~ is destroyed by proteasome \[[@r24]\]. However, the role of Ate1 and the Arg/N-end rule pathway in Aβ-associated neurotoxicity has not been fully explored. Additionally, Piatkov, *et al.* found that the Arg/N-end rule pathway counteracts apoptotic cell death by degrading proapoptotic protein fragments generated by caspase activation. They showed that caspases were capable of inactivating Ate1 as well as additional components of the Arg/N-end rule pathway suggesting a mutual suppression between proapoptotic signaling and the N-end rule pathway \[[@r23]\]. We hypothesize that the apoptosis-inducing effect of Aβ is mediated through the inhibition of the Arg/N-end rule pathway of the UPS.

To test this hypothesis, we examined the Arg/N-end rule pathway in the presence of Aβ~42~ or its pathogenic mutant carrying the 'English' mutation H6R (H6R-Aβ~42~), which is more amyloidogenic and is associated with early-onset AD \[[@r33]--[@r35]\]. We found that the apoptotic effects of Aβ peptides are associated with decreased Atel activity and inhibition of protein degradation via the Arg/N-end rule pathway.

RESULTS
=======

Aβ peptides inhibit the proteolytic activity of the Arg/N-end rule pathway
--------------------------------------------------------------------------

To evaluate the ability of Aβ~42~ and H6R-Aβ~42~ to modulate activity of the Arg/N-end rule pathway the ubiquitin reference technique (URT) was used \[[@r36]\]. This technique is based on the comparison of degradation rates of a test protein with a destabilizing N-terminal residue and a reference protein, which is not recognized by components of the N-end rule pathway. In this study we utilized ^f^DHFR-Ub^R48^, a flag-tagged derivative of the mouse dihydrofolate reductase as a reference protein, and PTPRN (Ica512) fragment as a test protein. As was shown earlier, calpain-generated Lys~609~-PTPRN fragment is a short-lived substrate of the Arg/N-end rule pathway \[[@r23]\]. In the URT-based pulse-chase assays the ^f^DHFR-Ub^R48^-X~609~-PTPRN^f^ (X = Asp, Arg-Asp) fusion protein is co-translationally cleaved by deubiquitilases, yielding equimolar quantities of the test and reference proteins ([Fig. 1A](#f1){ref-type="fig"}). The labeled test protein was quantified by measuring its level relative to the level of a stable reference at the same time point.

![**Inhibition effect of Aβ~42~ (10 μM) on the proteolytic activity of the Arg/N-end rule pathway.** (**A**) Diagram of the ^f^DHFR-Ub^R48^-X~609~-PTPRN^f^ (X = Asp, Arg-Asp) fusion. Co-translational cleavage of the fusion by deubiquitylases produces a test protein X~609~-PTPRN^f^ and a stable 'reference' protein ^f^DHFR-Ub^R48^ at the initially equimolar ratio. (**B**) Degradation of Asp~609~-PTPRN^f^ in reticulocyte lysate in the presence or absence of Aβ~42~. Asp~609~-PTPRN^f^ was expressed in reticulocyte lysate and co-translationally labeled with ^35^S-Met for 30 min at 30°C in the presence or absence of Aβ~42~, followed by a chase, immunoprecipitation with anti-flag M2 antibody, SDS-PAGE, and autoradiography. (**C**) Same as (B) but with Arg-Asp~609~-PTPRN^f^ fragment. (**D**) Quantification of (B). The level of Asp~609~-PTPRN^f^ was normalized on the level of ^f^DHFR-Ub^R48^. The level of Asp~609~-PTPRN^f^ detected immediately after stopping of protein expression in reticulocyte lysate (0 min chase) was taken as 100%. \"% remaining\" is the level of non-degraded Asp~609~-PTPRN^f^ at shown time points after stopping of protein expression. The absence of Aβ~42~ - dark-gray column; the presence of Aβ~42~ -- light-gray column. (**E**) Quantification of (C). Each value is the mean ± SD of at least three independent experiments; \*p \< 0.01, \*\*p \< 0.001.](aging-11-102177-g001){#f1}

The N-terminal amino acid residues of the test protein X~609~-PTPRN^f^ were Asp, which required Ate1 for degradation by the Arg/N-end rule pathway, and Arg, which bypasses the need for Ate1 and is directly recognized by the Arg/N-end rule E3 ubiquitin ligases \[[@r17]\]. In the absence of amyloid peptides both Asp-PTPRN^f^ and Arg-PTPRN^f^ are rapidly degraded in the URT-based pulse-chase assays (initial posttranslational t~1/2~ \~60 min for Asp~609~-PTPRN^f^ and \~14 min for Arg-Asp-PTPRN^f^) ([Fig. 1B, C, D, E](#f1){ref-type="fig"}). In the presence of Aβ~42~ however, degradation of Asp-PTPRN^f^ was completely inhibited whereas Arg-PTPRN^f^ was unchanged ([Fig. 1B, C, D, E](#f1){ref-type="fig"}), which suggests that Aβ~42~ disrupts the arginylation of proteins.

H6R-Aβ~42~ had significantly stronger inhibitory effects on the degradation of Asp~609~-PTPRN^f^ compared to Aβ~42~. Thus IC~50~ (half maximal inhibitory concentration) for H6R-Aβ~42~ is 1.83 ± 0.56 μM compared to 4.27 ± 0.15 μM for Aβ~42~ ([Fig. 2](#f2){ref-type="fig"}).

![**Effect of different concentrations of amyloid peptides on the proteolytic activity of the Arg/N-end rule pathway.** Degradation of ^35^S-methionine labeled Asp~609~-PTPRN^f^ in the presence of Aβ~42~ (**A**) or H6R-Aβ~42~ (**B**) was assayed as described in the legend to [Figure 1B](#f1){ref-type="fig"}. (**C**) -- quantification of (A) and (B) at 60 min chase (Aβ~42~ -- black squares, H6R-Aβ~42~ -- red circles). Each value is the mean expressed as a percentage of the level of Asp~609~-PTPRN^f^ at 0 min chase ± SD of at least three independent experiments.](aging-11-102177-g002){#f2}

Aβ~42~ interacts with the R-transferase Ate1
--------------------------------------------

It was shown earlier that different isoforms of Ate1 can arginylate Aβ~42~ with unequal effectiveness \[[@r24]\]. In this study we used the Ate1-3 and Ate1-1 isoforms. The Ate1-3 isoform is more effective in arginylating the peptide than Ate1-1 isoform. Interaction of Aβ~42~ with tRNA and Ate1 was probed using the sandwich ELISA method ([Fig. 3A](#f3){ref-type="fig"}). A pair of antibodies was used that recognize different segments of Aβ~42~, the N-terminal Aβ~1-17~ and C-terminal Aβ~36-42~. tRNA, Ate1 and their combination were added to Aβ~42~ bound to immobilized anti-Aβ~1-17~ antibodies. Interaction of any component of the reaction mixture with Aβ~42~ blocks binding of the anti-Aβ~36-42~ antibodies to the C-terminal segment of the peptide, as well as the secondary anti-rabbit antibodies, leading to decreased spectrophotometric signal. Addition of Ate1-1 or Ate1-3 significantly reduced optical density of the solution, indicating that the interaction of Aβ~42~ with detection antibodies was blocked by Ate1 ([Fig. 3C](#f3){ref-type="fig"}). In contrast, tRNA had no impact on the interaction of Aβ~42~ with detection antibodies. The concurrent addition of tRNA and Ate1-1 did not change the signal compared to control, however the combination of tRNA and Ate1-3 blocked the interaction of Aβ~42~ with detection antibodies similarly to Ate1-3 alone ([Fig. 3C](#f3){ref-type="fig"}).

![**Interaction of Aβ~42~, tRNA, and Ate1.** Schematic representation of ELISA assay with immobilized anti-Aβ1-17 antibodies (**A**) or anti-Aβ36-42 antibodies (**B**). (**C**) Detection of tRNA and Ate1 ability to interact with C-terminus of Aβ. (**D**) Same as (C) but with N-terminal region of Aβ. OD~450~ -- optical density measured at 450 nm. Each value is the mean ± SD of at least four independent experiments; \*p \< 0.04, \*\*p \< 0.01, \*\*\*p \< 0.001.](aging-11-102177-g003){#f3}

Interaction of the N-terminal region of Aβ~42~ with Ate1 isoforms and tRNA was studied using anti-Aβ~36-42~ as capture antibodies, and anti-Aβ~1-17~ as detection antibodies ([Fig. 3B](#f3){ref-type="fig"}). tRNA did not affect the interaction of Aβ~42~ with antibodies. We revealed cross-reactivity of Ate1 and secondary anti-mouse antibodies ([Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}). This effect was used to detect the binding of Ate1 with Aβ~42~. Addition of Ate1-1 or Ate1-3 significantly enhanced optical density of the solution, indicating that Ate1 isoforms interact with N-terminus of Aβ~42~ ([Fig. 3D](#f3){ref-type="fig"}). tRNA blocked the interaction of the amyloid peptide with both Ate1 isoforms.

Aβ peptides decrease enzymatic activity of Ate1
-----------------------------------------------

We examined the kinetic parameters of protein arginylation using isothermal titration calorimetry (ITC). ATP hydrolysis carried out by RS is an exothermic reaction ([Suppl. Fig. 2A, B](#SD1){ref-type="supplementary-material"}). Rate data for this reaction were fitted to the Michaelis-Menten equation, and kinetic constants were obtained ([Table 1](#t1){ref-type="table"}). Amyloid peptides were added to the calorimetric cell as a competitive inhibitor ([Suppl. Fig. 2C, D, E, F](#SD1){ref-type="supplementary-material"}). The K~I~ of RS for Aβ~42~ and H6R-Аβ~42~ were 157 and 161 μM, respectively ([Table 1](#t1){ref-type="table"}).

###### Inhibition effect of Аβ peptides on the enzyme kinetics of RS.

  ---------------- --------------- -------------------- --------------- -------------------
  **Inhibitior**   **K~m~ (µМ)**   **k~cat~ (s^-1^)**   **K~I~ (µМ)**   **ΔH (kcal/mol)**
  **-**            35.7 ± 1.2      0.56 ± 0.09          \-              -3.16
  **Аβ~42~**       \-              \-                   157.0 ± 5.2     -1.48
  **H6R-Аβ~42~**   \-              \-                   161.0 ± 1.3     -2.77
  ---------------- --------------- -------------------- --------------- -------------------

Comparison of the enzymatic kinetic parameters of Ate1 isoforms were carried out for its well-known substrate BSA \[[@r31],[@r32],[@r37]\] ([Suppl. Fig. 3A, B; 4A, B](#SD1){ref-type="supplementary-material"}), Аβ~42~ ([Suppl. Fig. 3C, D; 4C, D](#SD1){ref-type="supplementary-material"}) and H6R-Аβ~42~ ([Suppl. Fig. 3E, F; 4E, F](#SD1){ref-type="supplementary-material"}). For Аβ~42~ the values of k~cat~ for Ate1-1 and Ate1-3 were \~6- and \~13-fold lower than for BSA, respectively ([Table 2](#t2){ref-type="table"}). At the same time, K~m~ values for Аβ~42~ decreased \~8-fold for Ate1-1 and \~11-fold for Ate1-3 compared to BSA. Arginylation of H6R-Аβ~42~ proceeded at an even slower rate ([Table 2](#t2){ref-type="table"}), with k~cat~ values for Ate1-1 and Ate1-3 decreasing \~14-fold and \~55-fold, respectively; and K~m~ values decreasing \~14-fold and \~23-fold, respectively, relative to BSA.

###### Parameters of Ate1 enzyme kinetics.

  ---------------- ------------ --------------- -------------------- -------------------
  **Substrate**    **Enzyme**   **K~m~ (µМ)**   **k~cat~ (s^-1^)**   **ΔH (kcal/mol)**
  **BSA**          **Ate1-1**   33.2 ± 4.0      6.6 ± 0.6            5.87
  **Аβ~42~**       4.3 ± 0.5    1.07 ± 0.09     -10.4                
  **H6R-Аβ~42~**   2.4 ± 0.5    0.46 ± 0.05     -7.85                
  **BSA**          **Ate1-3**   52.5 ± 11.8     9.3 ± 1.7            5.78
  **Аβ~42~**       4.6 ± 0.3    0.70 ± 0.04     -9.77                
  **H6R-Аβ~42~**   2.3 ± 0.3    0.17 ± 0.03     -7.25                
  ---------------- ------------ --------------- -------------------- -------------------

Ate1 is required for apoptosis induced by amyloid peptides
----------------------------------------------------------

The apoptotic effect of Aβ peptides on differentiated mouse neuroblastoma Neuro-2a cells was assessed by flow cytometry after 20 hours of incubation of cells with peptides. We found that the percentage of early apoptotic wild type Neuro-2a cells (Annexin V^+^ propidium iodide^-^) increased \~2-fold (from \~6% to \~12%) in the presence of Аβ~42~ ([Fig. 4A](#f4){ref-type="fig"}). H6R-Aβ~42~ had an even greater effect as the number of early apoptotic wild type cells increased \~4-fold relative to untreated cells (from \~6% to \~24%) ([Fig. 4A](#f4){ref-type="fig"}) the number of late apoptotic cells increased 3-fold relative to control ([Suppl. Fig. 5A](#SD1){ref-type="supplementary-material"}). At the same time presence of Aβs results in increase the number of necrotic cells in population ([Suppl. Fig. 5C](#SD1){ref-type="supplementary-material"}). Consistent with the apoptotic effects of amyloid peptides being mediated through Ate1, we found no increase in percentage of early and late apoptotic Ate1-lacking Neuro-2a cells treated with either Aβ~42~ or H6R-Aβ~42~ ([Fig. 4B](#f4){ref-type="fig"}, [Suppl. Fig. 5B](#SD1){ref-type="supplementary-material"}). In the presence of H6R-Aβ~42~ the percentage of necrotic Ate1-lacking Neuro-2a cells increased, which may be due to its nonspecific membrane-damaging effect ([Suppl. Fig. 5D](#SD1){ref-type="supplementary-material"}).

![Apoptotic effects of Aβ peptides (10 µM, 20 h) on Neuro-2a (**A**) cells and Ate1 knockout Neuro-2a cells (**B**). The Annexin-V positive and PI negative cells were considered early apoptotic. Each value is expressed as a percentage of the total number of cells ± SD. The experiments were performed three times in triplicates; \*p \< 0.01, \*\*p \< 0.001.](aging-11-102177-g004){#f4}

DISCUSSION
==========

AD results from the progressive dysfunction and death of neurons associated with the amyloidogenic peptide, Aβ. A number of familial mutations of Aβ enhance its oligomerization and toxic properties, triggering the development of early-onset AD \[[@r38]--[@r41]\]. One of such mutations is the 'English' mutation defined by the H6R substitution (H6R-Aβ~42~) \[[@r33]\]. Many studies over the past decade have shown toxicity associated with Aβ in various oligomeric states \[[@r9],[@r42]--[@r44]\]. Large aggregates can result in mechanical damage of the cell membrane, leading to disruption of the ion homeostasis and necrosis. Small Aβ oligomers can bind to membrane receptors and/or penetrate cells where they disrupt function of the cellular systems and trigger apoptosis. One major anti-apoptotic systems in cells is the Arg/N-end rule pathway of the ubiquitin proteasome system, which degrades caspase-generated pro-apoptotic protein fragments. Indeed, even a partial inhibition of this pathway leads to the accumulation of pro-apoptotic protein fragments, an increase in caspase activation by positive feedback, and increased apoptosis \[[@r23]\]. In this study, we found that Aβ, and especially H6R-Aβ~42,~ induces cellular apoptosis by inhibiting protein arginylation by Ate1 and subsequent protein degradation through the Arg/N-end rule pathway.

The Arg/N-end rule dependent degradation of proteins (or protein fragments) bearing N-terminal Asp, Glu, or oxidized Cys requires their conjugation, by one of the *ATE1*-encoded isoforms of the arginyl-tRNA-protein transferase (Ate1) to arginine \[[@r17],[@r45]--[@r47]\]. This reaction also requires tRNA^Arg^ formed by aminoacyl-tRNA synthetases (RS). Mammals have at least six Ate1 isoforms produced through alternative splicing that differ by 1 and 7 exons \[[@r45]\]. The level of Ate1 isoforms significantly varies in different tissues and intracellular compartments, suggesting that specific isoforms may have distinct functions \[[@r46],[@r47]\]. All isoforms have different activity and substrate specificity \[[@r31],[@r46],[@r47]\]. It was shown that Ate1-2 and Ate1-3 arginylate Aβ~42~ with significantly higher efficiency than Ate1-1 and Ate1-4 \[[@r24]\].

We found that the amyloid peptides Aβ~42~ and H6R-Aβ~42~ had little effect on RS activity ([Suppl. Fig. 2](#SD1){ref-type="supplementary-material"}, [Table 2](#t2){ref-type="table"}) but were capable of binding the Ate1 isoforms 1-1 and 1-3 ([Fig. 3B](#f3){ref-type="fig"}). We also found that the presence of tRNA decreased Ate1-1, but not Ate1-3 binding to Aβ~42~ ([Fig. 3B](#f3){ref-type="fig"}). This may underlie the differences between Ate1-1 and Ate1-3 in their abilities to arginylate Aβ~42~ \[[@r24]\]. We also found that Aβ~42~ and H6R-Aβ~42~ have a higher affinity for Ate1 than BSA, a well-characterized substrate of Ate1 \[[@r31],[@r32],[@r37]\] ([Suppl. Fig. 3C, D, E, F](#SD1){ref-type="supplementary-material"}, [Fig. 4C, D, E, F](#f4){ref-type="fig"}, and [Table 2](#t2){ref-type="table"}). At the same time k~cat~ of Aβs arginylation was significantly lower than for BSA ([Table 2](#t2){ref-type="table"}). Finally, we found that Aβ peptides inhibited the degradation of substrate proteins bearing N-terminal Asp but had no effect on the degradation of proteins bearing primary destabilizing N-terminal amino acids directly recognized by E3 ubiquitin ligases of the Arg/N-end rule pathway (e.g. Arg). Collectively, these data indicate that amyloid peptides compete with natural Ate1 substrates resulting in their decreased arginylation and increased stability. In the case of pro-apoptotic protein fragments that require N-terminal arginylation for degradation by the Arg/N-end rule pathway, such competition by amyloid peptides increases the pro-apoptotic signal within cells. In support of this conclusion, using a genetic approach, we found that Aβ peptides induced the apoptosis of differentiated wild type Neuro-2a cells but not Neuro-2a cells in which Ate1 was ablated by Crispr/Cas9.

Apart from protein degradation by the Arg/N-end rule pathway, post-translational arginylation has been shown to be involved in a number of cellular processes including the modulation of the cell cytoskeleton \[[@r48],[@r49]\], regeneration of neural tissue in lesions \[[@r50]--[@r52]\], G-protein signaling \[[@r53],[@r54]\], and angiogenesis \[[@r55],[@r56]\]. Arginylation also plays a protective role in aging \[[@r57]\], stress response regulation \[[@r58]\] and in the prevention of protein aggregation in neurodegeneration \[[@r59]\]. Recently, N-terminal arginylation by Ate1 was shown to signal protein degradation via the autophagy system \[[@r60]--[@r62]\] as well. Dysfunction of UPS leads to accumulation of misfolded or damaged proteins in cells. This stimulates translocation of endoplasmic reticulum chaperones, such as BiP, into the cytoplasm where they bind unwanted proteins. Their N-terminal arginylation mediated by Ate1 activates autophagic adaptor p62/STQSM/Sequestosome-1, promoting autophagic flux and lysosomal degradation \[[@r60],[@r62],[@r63]\]. As such, a decrease in protein arginylation by Ate1 activity caused by amyloid peptides may affect a wide array of cellular processes leading to apoptosis.

In conclusion, we suggest that the following succession of events takes place in the cell affected by amyloid peptides. Pathological processes invoked by AD lead to the accumulation of Aβ in the cells \[[@r64]--[@r68]\]. When a critical concentration of Aβ is reached, Ate1 function is disrupted, leading to the stabilization of misfolded and toxic proteins, including pro-apoptotic protein fragments otherwise degraded by the Arg/N-end rule pathway, triggering apoptosis leading to neuronal cell death.

MATERIALS AND METHODS
=====================

Plasmids and primers
--------------------

43-kDa mouse X~609~-PTPRN (X=Asp, Arg-Asp) fragment was amplified by polymerase chain reaction (PCR) using following primers: AAAAACCGCGGAGGAGATGAGCGCCTGGCAGCGCTGGGGC and TTTTAATCGATCTGGGGCAGGGCCTTGAGGAT for Asp~609~-PTPRN; AAAAACCGCGGAGGACGTGATGAGCGCCTGGCAGCGCTGGGGC and TTTTAATCGATCTGGGGCAGGGCCTTGAGGAT for Arg-Asp~609~-Ica512. Encyclo polymerase (Evrogen) was used for PCR. The resulting PCR products were cut with SacII/ClaI and cloned into SacII/ClaI-cut pKP496 \[[@r36]\]. Turbo *E. сoli* (NEB) was used for cloning and maintaining plasmids. Sequences of all constructed plasmids were verified by DNA sequencing. Plasmids pCB407 and pCB409 encoding Ate1 isoforms were described previously \[[@r69]\].

Preparation of Aβ peptides
--------------------------

Synthetic peptide Aβ~42~: \[H~2~N\]-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-\[COOH\] and its mutant H6R-Aβ~42~: \[H~2~N\]-DAEFRRDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-\[COOH\] were purchased from Biopeptide. Monomerization of Aβ peptides was performed as described previously \[[@r70]\]. Briefly, chilled hexafluoroisopropanol (HFIP, Fluka) was added to solid Aβ peptide to a concentration of 1 mM and incubated for 60 min at room temperature. Then this solution was put on ice for 10 min and aliquoted into non-siliconized microcentrifuge tubes (0.23 mg peptide per tube). HFIP evaporated overnight in the hood at room temperature. Peptide in the tubes was dried under vacuum using Eppendorf Concentrator 5301 to remove traces of HFIP. Dried peptide was stored at -80°C. 5 mM peptide stock solution was prepared by adding 10 μl of 100% anhydrous DMSO (Merck) to 0.23 mg peptide and incubating for 60 min at room temperature.

For arginyltransferase (Ate1) kinetics measurements Aβ peptides were dissolved in 10% NH~4~OH in a concentration of 1 mM and incubated for 60 min at room temperature. The solution was frozen at -196°C and lyophilized to remove the solvent. Dried peptides were resuspended in reaction buffer. Only freshly prepared peptide solutions were used for all experiments.

*In vitro* Transcription-Translation-Degradation assay
------------------------------------------------------

The TNT T7 Coupled Reticulocyte Lysate System (Promega) was used to carry out transcription-translation-degradation assays as described elsewhere \[[@r24]\]. Reaction samples were prepared according to the manufacturer's instruction. Aβ peptides or equivalent amount of DMSO (control) were added to the samples. Nascent proteins in reticulocyte lysate were pulse-labeled with L-\[^35^S\]-methionine (10.2 mCi/ml, 1000 Ci/mmol, PerkinElmer) for 30 min at 30 °C, in the total volume of 17 μl. The labeling was quenched by the addition of 6.2 μl of chase medium (0.8 mg/ml cycloheximide, 8.3 mM unlabeled methionine, 4.2 mM ATP, 66.7 mM phosphocreatine, 0.3 mg/ml creatine kinase, 8.3 mM MgCl~2~, Aβ peptides or DMSO in required concentration). Samples were taken at indicated time points of a chase and the reactions were terminated by the addition of 80 μl of TSD buffer (1% SDS, 5 mM dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4) and snap-freezing in liquid nitrogen. Samples were then heated at 95°C for 10 min, diluted with 1 ml of TNN buffer (0.5% NP-40, 0.25 M NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.4), containing the "complete protease inhibitor mixture" (Roche), clarified by centrifugation at 15000 g for 5 min and immunoprecipitated using 5 μl of anti-flag M2 Magnetic Beads (Sigma). The samples were incubated with rocking at 4°C for 3 h, followed by 3 washes in TNN buffer, one wash in 10 mM Tris-HCl (pH 8.5), and eluted in 20 μl of SDS-sample buffer. Samples were then heated at 95°C for 10 min and fractionated by 10% SDS-PAGE, followed by autoradiography, using Typhoon FLA 9500 (GE Healthcare), and quantification, using ImageJ.

Cell culture
------------

Mouse neuroblastoma Neuro-2a cells were cultured at 37°C in 5% CO~2~ in DMEM medium supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin (Invitrogen), 0.1 mg/ml streptomycin (Invitrogen) and 2 mM glutamine (PanEko). For differentiation cells were grown in the medium containing 1% FBS for 2 days. The medium was replaced with a serum-free medium prior to adding amyloid peptides.

Generation of Ate1 knockout Neuro-2a cells
------------------------------------------

Mouse neuroblastoma Ate1-lacking Neuro-2a cells were generated using the CRISPR/Cas9 system and were described previously \[[@r71]\].

Flow cytometry
--------------

Flow cytometry analysis was performed to determine the percent of apoptotic cells and cells with damaged membrane by double staining with Pacific Blue conjugated Annexin-V (Molecular Probes) and propidium iodide (PI; Sigma). The cells were first washed with PBS at 4°C and resuspended in 0.1 ml (1×10^6^ cells/ml) of buffer-A (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl~2~, pH 7.4). Then, they were incubated with 5 μl of Pacific Blue-conjugated Annexin V (Ex/Em 410/455 nm) for 15 min at room temperature in darkness. 400 μl of buffer-A was added and cells were incubated with 10 μg/ml PI (Ex/Em 493/632 nm) for 1--2 min before analysis in a BD LSRFortessa flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Tree Star, Inc). The Annexin-V positive and PI negative cells were considered early apoptotic. Cells in subpopulations were expressed as a percentage of the total number of cells. The experiments were repeated thrice with triplicates and values were expressed as mean ± SD.

Ate1 expression and purification
--------------------------------

Mouse Ate1 isoforms (Ate1^1B7A^ and Ate1^1A7A^) were expressed and purified as described previously \[[@r72]\] with modifications. An overnight culture of transformed Rosetta^TM^(DE3)pLysS *E. coli* cells was split 1:100 into 400 ml of LB medium supplemented with standard concentrations of ampicillin and chloramphenicol, followed by growth at 37°C for 1-2 hours until A~600~ of ∼0.7. Expression was induced with 0.5 mM IPTG (isopropyl b-D-thiogalactoside), the culture was cold shocked on ice for 30 min, and then growth at 22°C for 15 h. For Ate1 purification, cells were collected by centrifuging at 4000 rpm for 20 min, resuspended in lysis buffer (10% glycerol, 0.05% Nonidet P-40, 500 mM NaCl, 20 mM imidazole, 5 mM β-mercaptoethanol, 50 mM Na~2~HPO~4~/NaH~2~PO~4~, pH 8.0) containing 1 mg/ml of lysozyme and "complete protease inhibitor mixture" (Roche), followed by brief sonication. The lysate was centrifuge at 12000 g for 20 min, 4°C and incubated for 1 h at 4°C with Ni-NTA agarose (GE Healthcare) equilibrated with the lysis buffer. The resin was washed three times with the lysis buffer containing 50 mM imidazole. Proteins were eluted with lysis buffer containing 250 mM imidazole, followed by overnight dialysis at 4°C against 50 mM Na~2~HPO~4~/NaH~2~PO~4~, pH 7.5 containing 10% glycerol, 0.05% Nonidet P-40, 300 mM NaCl, 5 mM β-mercaptoethanol. The tagged Ub moiety was cleaved off during dialysis by incubation with Usp2-cc (1:100), a deubiquitylating enzyme that has been expressed and purified as previously described \[[@r73]\]. To eliminate His-tagged Ub and Usp2-cc proteins were incubated with Ni-NTA agarose equilibrated with the dialysis buffer, followed by washing in dialysis buffer containing 500 mM NaCl. Untagged Ate1 isoforms were eluted with dialysis buffer containing 500 mM NaCl, 50 mM imidazole and then dialyzed against 50 mM Na~2~HPO~4~/NaH~2~PO~4~, pH 7.5 containing 150 mM NaCl, 5 mM MgCl~2~, 2 mM DTT, 20% glycerol for 2 h at 4°C. Glycerol was added to the dialyzed samples to a final concentration of 50%. Purified Ate1 isoforms were kept at -80°C. The estimated purity of each protein was \>90%.

Enzyme kinetic activity
-----------------------

The enzymatic kinetics was measured using a MicroCal PEAQ-ITC (Malvern). Experiments were carry out at 37°C in 50 mM Hepes, pH 7.5, 30 mM KCl, 5 mM MgCl~2~, 1 mM DTT and 200 μM L-arginine. Single aliquot (8 μl, 16s) of the 5 mM BSA or 1.25 mM Aβ peptides was injected from the syringe into the 0.2 ml cell containing 1 μM of Ate1, 50 μM ATP, 100 μM total *E. coli* tRNA (Sigma), 1 μM total *E. coli* aminoacyl-tRNA synthetases (RS). To evaluate inhibition effect of Aβ peptides on the RS enzymatic activity 8 μl of 10 mM ATP was injected into mixture of 1 μM RS and 1 mM tRNA in the presence and absence of inhibitor (100 μM Aβ). The resulting kinetic curves were fitted using MicroCal PEAQ-ITC Analysis Software (Malvern). Michaelis constants (K~M~), catalytic rate constants for substrate conversion (k~cat~) and inhibition constants (K~I~) were determined by non-linear least squares. To calculate the K~I~ values, the kinetic parameters for RS obtained in the absence of amyloid peptides were used.

ELISA
-----

All antibodies used in ELISA assays are listed in [Table 3](#t3){ref-type="table"}. 96-well plate (Thermo Scientific Nunc MaxiSorp Surface) was coated overnight with 50 μl of capture antibody (2 μg/ml) followed by washing with phosphate-buffered saline containing 0.05% Tween (PBST) and incubation with 100 μl of blocking buffer for 2 h. One hundred microliters of 1 μM Aβ was added to the wells for 90 min at 37°C. After washing, the wells were additionally incubated with buffer (30 mM KCl, 5 mM MgCl~2~, 15 μM Arg, 1mM ATP, 50 mM Hepes, pH 7.5), Arg-tRNA or Ate1 for 90 min at 37°C. To synthetize Arg-tRNA total tRNA was first incubated with RS (1000 u/ml) and 50 mM Hepes, pH 7.5 containing 50 μM Arg, 2.5 mM ATP, 2 mM DTT, 5mM MgCl~2~ and 30mM KCl at 37°C for 60 min, then purified away from the proteins using phenol/chlorophorm extraction. All wells were washed three times with 200 μl of PBST. 100 μl of detection antibody (0.7 μg/ml) was added to each well and incubated for 2 h. After washing, 100 μl of horseradish peroxidase (HRP)-conjugated antibody diluted at the optimal concentration in blocking buffer was incubated with samples for 1 h. For detection OPD (o-phenylenediamine dihydrochloride, Thermo Scientific) was used according to manufacturer's instruction. Absorbance values were measured at 450 nm by a Multiskan™ GO Microplate Spectrophotometer (Thermo Scientific).

###### Antibodies used in ELISA assays.

  --------------------------------------- ------------------- ------------------------------------------------ --------------
  **Antibody**                            **Host**            **Manufacturer**                                 **Dilution**

  **Capture Antibody**                                                                                         

  **anti-Aβ~1-17~ (DE2B2)**               Mouse monoclonal    Thermo Fisher Scientific, USA cat. \#MA1-24966   1:500

  **anti-Aβ~36-42~**                      Rabbit polyclonal   Thermo Fisher Scientific, USA cat. \#44-344      1:500

  **Detection Antibody**                                                                                       

  **anti-Aβ~36-42~**                      Rabbit polyclonal   Thermo Fisher Scientific, USA cat. \#44-344      1:1500

  **anti-Aβ~1-17~ (DE2B2)**               Mouse monoclonal    Thermo Fisher Scientific, USA cat. \#MA1-24966   1:1500

  **Secondary HRP-conjugated Antibody**                                                                        

  **anti-rabbit**                         Donkey polyclonal   Novex, USA\                                      1:10000
                                                              cat. \#A16035                                    

  **anti-mouse**                          Rabbit polyclonal   Imtek, RF\                                       1:10000
                                                              cat. \#RAM Iss                                   
  --------------------------------------- ------------------- ------------------------------------------------ --------------

Statistical analysis
--------------------

The data are shown as the mean ± standard deviation at least of three independent experiments. The differences among the groups were analyzed using One Way ANOVA with post-hoc Tukey HSD (Honestly Significant Difference) test.
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